Clinical Data GSK hails ‘unprecedented’ cure rates with hep B drug PharmaphorumThe B-Well trials of GSK's bepirovirsen position the antisense drug as a "major step towards a cure for hepatitis B infection," according to experts.Infectious DiseaseRead full story pharminent May 28, 2026 (Last updated: May 28, 2026) Pharmaphorum The B-Well trials of GSK’s bepirovirsen position the antisense drug as a “major step towards a cure for hepatitis B infection,” according to experts. Infectious Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: AbbVie snags FDA’s first ADC approval for ultra-rare blood cancerNext: CVS obesity drug deal puts Lilly on equal footing with Novo Related Stories Clinical Data Early data for heart drug affirm Lilly’s billion-dollar bet on Verve pharminent May 26, 2026 Clinical Data Arthrosi drug trial in gout delivers for new owner Sobi pharminent May 26, 2026 Clinical Data Lilly’s Verve gambit pays off as base editor cuts cholesterol in early study pharminent May 26, 2026
